Telomir Pharmaceuticals, Inc. · NASDAQ:TELO
Telomir Pharmaceuticals — Investor Presentation (November 2025)
63 slides from Telomir Pharmaceuticals's investor presentation, November 2025
Slide 1: Designed to reverse cellular aging
Designed to reverse cellular aging... November 2025 Nasdaq: TELO
Slide 2: Corporate Overview
CORPORATE OVERVIEW Telomir Pharmaceuticals Inc. (Nasdaq: TELO) is Cancer Wilson’s Disease a pre-clinical-stage pharmaceutical company leading the development of age-reversal science by focusing on addressing the root causes of age-related conditions, rather than just managing the Symptoms. T E L O M
Slide 3: Telomir Management
TELOMIR MANAGEMENT Erez Aminov | Chairman & CEO Itzchak Angel, PhD | Chief Scientific Advisor § A biotechnology leader driving innovation in drug § Over 40 years of experience in guiding medical, development and strategic growth. pharmaceutical, drug, and business development in both large and emerg
Slide 4: Therapeutic Research Approaches for Telomir-1
THERAPEUTIC RESEARCH Explore the interactions APPROACHES T E L O M I R P H A R M A . C O M Investigating Telomir-1’s between iron, copper and zinc effects on copper and iron FOR TELOMIR-1 regulation at the cellular level on variable cellular functions focusing on cancer, cellular and in preclinical
Slide 5: Impact of Iron Overload
IMPACT OF IRON OVERLOAD Cellular § Oxidative stress § Mitochondrial dysfunction § DNA dysfunction § Epigenetics § Ferroptosis § Cellular senescence T E L O M I R P H A R M A . C O M Functional § Cancer § Accelerated aging Pathology § Senescence § Cancer § Telomer shortening § Progeria and Werner § I
Slide 6: Impact of Iron and Copper Overload
Iron and copper overload contribute to AMD and retinal aging, while copper IMPACT OF IRON AND COPPER OVERLOAD overload is also central to Wilson’s disease and broader age-related neurodegenerative processes. IRON OVERLOAD COPPER OVERLOAD Cancer T E L O M I R P H A R M A . C O M Accelerated Aging Can
Slide 7: Therapeutic Areas
THERAPEUTIC AREAS Key ongoing initiatives include: Cancer Models Exploring epigenetic mechanisms and anti-cancer applications using in vitro and xenograft studies. Alzheimer’s Disease, Spasmodic Wilson’s Disease Study T E L O M I R P H A R M A . C O M Dysphonia and other neuronal and Investigating T
Slide 8: Pre-Clinical Research
Our molecule, Telomir-1 can effectively bind and chelate several ions. It has high affinity for PRE-CLINICAL RESEARCH iron and copper and lower affinity for zinc. Age Reversal and Increased Longevity T E L O M I R P H A R M A . C O M White: Hydrogen Blue: Nitrogen Gray: Carbon Orange: Metal Investor
Slide 9: Pre-Clinical Research: Effective iron and copper chelation
Our molecule, Telomir-1 can effectively bind PRE-CLINICAL RESEARCH and chelate several ions. It has high affinity for Effective iron and copper chelation iron and copper and lower affinity for zinc. T E L O M I R P H A R M A . C O M Zinc does not compete Copper competes with with iron on the binding
Slide 10: Mechanisms of action
PRE-CLINICAL RESEARCH Mechanisms of action Telomir-Zn, a lipophilic form of Telomir-1, readily enters cells and leverages its higher affinity for iron and copper over zinc to exchange harmful iron or copper ions with beneficial zinc. This exchange mechanism allows Telomir-Zn to chelate and remove ex
Slide 11: Reduction of intracellular iron levels
PRE-CLINICAL RESEARCH Mechanisms of action –Reduction of intracellular Iron levels. Measurements of intracellular iron in HaCat cells Direct measurements of the effects of Telomir-1 on intracellular iron, as stained with FerroOrange at 24 hours. T E L O M I R P H A R M A . C O M High intracellular i
Slide 12: Reduction of intracellular iron levels (16 hours)
PRE-CLINICAL RESEARCH Mechanisms of action –Reduction of intracellular Iron levels. Measurements of intracellular iron in HaCat cells Direct measurements of the effects of Telomir-1 and DFO on intracellular iron, as stained with FerroOrange at 16 hours. While Deferoxamine (DFO) is more potent chelat
Slide 13: Reduction of intracellular iron levels (6 hours)
PRE-CLINICAL RESEARCH Mechanisms of action –Reduction of intracellular Iron levels. Measurements of intracellular iron in HaCat cells Direct measurements of the effects of Telomir-1 and DFO on intracellular iron, as stained with FerroOrange at 6 hours. While Deferoxamine (DFO) is more potent chelato
Slide 14: Reduction of intracellular iron levels (3 hours)
PRE-CLINICAL RESEARCH Mechanisms of action –Reduction of intracellular Iron levels. Measurements of intracellular iron in HaCat cells Direct measurements of the effects of Telomir-1 and DFO on intracellular iron, as stained with FerroOrange at 3 hours. While Deferoxamine (DFO) is more potent chelato
Slide 15: Aging and longevity research
PRE-CLINICAL RESEARCH Aging and longevity research T E L O M I R P H A R M A . C O M • Telomers • Life-span and activity + • Mechanisms of action Investor Presentation | Nasdaq: TELO 08
Slide 16: What Are Telomeres?
WHAT ARE TELOMERES? Age Reversal and Increased Longevity Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins (TTAGGG). Female Male XX XY T E L O M I R P H A R M A . C O M § Telomeres protect chromosome ends during cell division, preventing gene Genetic loss, l
Slide 17: Telomir-1 Restores Telomere Length in Accelerated Aging Models
Telomir-1 Restores Telomere Length in Accelerated Aging Models Telomir-1 reverses telomere shortening and restores length beyond wild-type levels in models mimicking Progeria and Werner syndromes. Reversal by Telomir-1 of shortened telomer length in an accelerated aging model in zebra fish Study Mod
Slide 18: Pre-Clinical Research: Age Reversal and Increased Longevity
High-dose Telomir-1 significantly extended nematode PRE-CLINICAL RESEARCH lifespan by ~2.5 days, demonstrating a strong longevity effect. Age Reversal and Increased Longevity Study Overview This preclinical study, in collaboration with Nagi Bioscience, used an in vivo microfluidic-based assay to eva
Slide 19: Study in Adult Progeria
PRE-CLINICAL RESEARCH Age Reversal and Increased Longevity Study in Adult Progeria - Summary and Methodology The preclinical study with Nagi Bioscience SA used C. elegans with a wrn-1 gene mutation, the human equivalent of which is linked to Werner Syndrome (Adult Progeria), showing reduced life exp
Slide 20: Telomir-1 normalizes reduced viability in progeria cells
Telomir-1 normalizes reduced viability induced by copper and iron in progeria cells Protective and regulatory effect observed at low Telomir-1 concentrations 0.80 Conc Study Summary: Telomir • Progeria fibroblasts were treated with increasing 0.70 (µM) concentrations of Telomir-1 following exposure
Slide 21: Telomir-1 Reduces ROS and Reverses Oxidative Stress
Telomir-1 Reduces ROS and Reverses Oxidative Stress Induced by Copper and Iron ROS modulation observed under both basal and metal- induced stress conditions 400,000 Conc Telomir Study Summary: 350,000 (µM) • Progeria fibroblasts were evaluated for reactive oxygen species (ROS) levels 24 hours after
Slide 22: Telomir-1 Protects Progeria Cells from Mitochondrial Stressors
Telomir-1 Protects Progeria Cells from Multiple Mitochondrial Stressors Dose-dependent normalization of intracellular calcium linked to mitochondrial protection 1.5 Study Summary: • We studied the effects of Telomir-1 on Progeria 0 fibroblasts, evaluating key parameters of 1.4 mitochondrial health a
Slide 23: Telomir-1 activates Mitochondrial activity in Progeria Cells
Telomir-1 activates Mitochondrial activity in Progeria Cells Dose-dependent normalization of intracellular calcium Augmentation of mitochondrial activity linked to mitochondrial protection Study Summary: Progeria cells • We studied the effects of Telomir-1 on Progeria fibroblasts, T E L O M I R P H
Slide 24: Telomir-1 activates Mitochondrial activity in Progeria Cells
Telomir-1 activates Mitochondrial activity in Progeria Cells Dose-dependent normalization of intracellular calcium Augmentation of mitochondrial activity linked to mitochondrial protection Study Summary: • We studied the effects of Telomir-1 on Progeria fibroblasts, evaluating key parameters mitocho
Slide 25: Anti-Cancer Activity in Prostate Cancer Model
PC3 tumor growth in vitro PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 Demonstrates Promising Efficacy in Aggressive Human Prostate Cancer Model (PC3 cells) Key Study Highlights: T E L O M I R P H A R M A . C O M Model Used: Preclinical in vitro study usi
Slide 26: Cancer Research
PRE-CLINICAL RESEARCH Cancer Research T E L O M I R P H A R M A . C O M • Anti-cancer activity • Epi-genetics + • Mechanisms of action Investor Presentation | Nasdaq: TELO 08
Slide 27: Anti-Cancer Activity in Triple Negative Breast Cancer Cells
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Triple negative breast cancer (TNBC) cells Telomir-1 kills TNBC cells and this effect is MDA MB 231 cell viability protected by iron Key Study Highlights: Model Used: In vitro studies in human TNBC cells (MDA MB T E L O M I R P H A R M A . C
Slide 28: Anti-Cancer Activity in Prostate Cancer: Tumor Growth in Mice
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model PC3 tumor growth in mice Telomir-1 Demonstrates Promising Efficacy in Aggressive Human Prostate Cancer Model Key Study Highlights: T E L O M I R P H A R M A . C O M Model Used: Preclinical in vivo study using human prost
Slide 29: Prostate Cancer Model: DNA Methylation
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Exploring the role of DNA-methylation in DNA methylation of key proteins Aggressive Human Prostate Cancer Model and their respective functions Key Highlights: In prostate cancer, aberrant DNA methylation is a central T E
Slide 30: Telomir-1 reduces STAT1 DNA methylation
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 reduces Stat-1 DNA methylation at day 21 Telomir-1 Demonstrates Promising reduction of STAT1 hypermethylation in Aggressive Human Prostate Cancer Model Key Study Highlights: T E L O M I R P H A R M A . C O M ST
Slide 31: Telomir-1 reduces CDKN2A DNA methylation
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 reduces CDKN2A DNA methylation at day 21 Telomir-1 Demonstrates reduction of CDKN2A hypermethylation in Aggressive Human Prostate Cancer Model Key Study Highlights: T E L O M I R P H A R M A . C O M The CDKN2A
Slide 32: Telomir-1 reduces TMS1 DNA methylation
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 reduces TMS1 DNA methylation at day 21 Telomir-1 Demonstrates reduction of TSM1 hypermethylation in Aggressive Human Prostate Cancer Model Key Study Highlights: T E L O M I R P H A R M A . C O M TMS1 (also know
Slide 33: Telomir-1 reduces GSTP1 DNA methylation
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 reduces GSTP1 DNA methylation at day 21 Telomir-1 Demonstrates reduction of GSTP1 hypermethylation in Aggressive Human Prostate Cancer Model Key Study Highlights: GSTP1 (Glutathione S-Transferase Pi 1) T E L O
Slide 34: Telomir-1 reduces RASSF1A DNA methylation
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 reduces RASSF1A DNA methylation at day 21 Telomir-1 Demonstrates reduction of RASSF1A hypermethylation in Aggressive Human Prostate Cancer Model Key Study Highlights: T E L O M I R P H A R M A . C O M RASSF1A (
Slide 35: Telomir-1 reduces MASPIN DNA methylation
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 reduces MASPIN DNA methylation at day 21 Telomir-1 Demonstrates reduction of MASPIN hypermethylation in Aggressive Human Prostate Cancer Model Key Study Highlights: T E L O M I R P H A R M A . C O M MASPIN (Ser
Slide 36: Telomir-1 reduces CASP8 DNA methylation
PRE-CLINICAL RESEARCH Significant Anti-Cancer Activity in Prostate Cancer Model Telomir-1 reduces CASP8 DNA methylation at day 21 Telomir-1 Demonstrates reduction of CASP8 hypermethylation in Aggressive Human Prostate Cancer Model Key Study Highlights: T E L O M I R P H A R M A . C O M CASP8 (Caspas
Slide 37: Interaction with key epigenetic enzymes
PRE-CLINICAL RESEARCH Interaction with key epigenetic enzymes Exploring the role of Histone demethylases Key Histon Demethylase families and their respective functions Key Highlights: Histone demethylases (KDMs) remove methyl groups from lysine residues on histone tails, reversing the T E L O M I R
Slide 38: Telomir-1 potently inhibits histone demethylases KDM2 and KDM6
PRE-CLINICAL RESEARCH Telomir-1 potently inhibits Histon Significant epigenetic Activity demethylases (KDMs) KDM2 and KDM6 Telomir-1 was shown to inhibit histone demethylases. These are epigenetic enzymes that play critical roles in DNA methylation, gene regulation, cancer, neurodegeneration, metabo
Slide 39: Telomir-1 potently inhibits histone demethylases 5 (KDM5s)
PRE-CLINICAL RESEARCH Significant epigenetic Activity Telomir-1 potently inhibits Histon demethylases 5 (KDM5s, JARID1) Telomir-1 was shown to also inhibit histone demethylases 5 (JARID1). jARID1A, JARID1B, and JARID1C (also known as KDM5A, KDM5B, and KDM5C) are members of the KDM5 (lysine demethyla
Slide 40: Telomir-1 only mildly inhibits Tankyrases (PARP5)
PRE-CLINICAL RESEARCH Interaction with key epigenetic enzymes Telomir-1 only mildly inhibits Tankyrases (PARP5) Telomir-1 demonstrated low-level inhibitory activity against Tankyrases (PARP5A and PARP5B). Tankyrases regulate the Wnt/β-catenin pathway — one of the body’s key growth-control circuits t
Slide 41: Telomir-1 has low affinity for mTOR
PRE-CLINICAL RESEARCH Telomir-1 has low affinity for mTOR Interaction with key epigenetic enzymes and does not affect GCN5L2 or HCT-116 CDKN1A (p21) Telomir-1 did not show any activity against GCN5L2 (KAT2A), a broad acetyltransferase enzyme, whose inhibition is associated with widespread toxicity.
Slide 42: No agonist or antagonist activity on Keap1-Nrf2
PRE-CLINICAL RESEARCH Telomir-1 has no agonist or antagonist Interaction with key epigenetic enzymes activities on Keap1-Nrf2 Telomir-1 did not show any direct agonist or antagonist activity against Keap1-Nrf2 . The Keap1-Nrf2 pathway is a crucial regulator of cellular defense against oxidative stre
Slide 43: Multifactorial interaction of DNA-methylation, KDMs and Tankyrases
PRE-CLINICAL RESEARCH Multifactorial interaction of DNA-methylation, KDMs and Tankyrases on key processes GSTP1 CASP8 CANCER RASSF1A MASPIN AGING Oncogenic STAT1 CDKN2A Epigenetic drift T E L O M I R P H A R M A . C O M Tumor promoting Activation of senescence genes Tumor plasticity Accelerated agin
Slide 44: Additional Potential Indications
PRE-CLINICAL RESEARCH Additional Potential Indications T E L O M I R P H A R M A . C O M • Type two diabetes • Age related macular degeneration (AMD) • Wilson’s disease • Progeria and Werner’s syndrome Investor Presentation | Nasdaq: TELO 08
Slide 45: Reversal of Key Type 2 Diabetes Parameters
Reversal of insulin resistance (HOMA-IR) PRE-CLINICAL RESEARCH Reversal of Key Type 2 Diabetes Parameters Study Overview and Results In collaboration with Pentagrit, Telomir evaluated two forms of Telomir-1, administered orally at three different doses, in zebrafish models of Type 2 diabetes mellitu
Slide 46: Telomir-1 protects from copper induced oxidative stress in Retinal cells
Telomir-1™ protects from copper induced oxidative stress in Retinal cells Study Overview • Model: ARPE-19 retinal cells are incubated with varying concentrations of Telomir-1 and without Copper (25 µM) and levels of reactive oxygen species (ROS) was monitored, Cellular Recovery • Telomir-1 by itself
Slide 47: Telomir-1 protects from copper and iron induced calcium overload
Telomir-1™ protects from copper and iron induced calcium overload in Retinal cells Study Overview • Model: ARPE-19 retinal cells are incubated with varying concentrations of Telomir-1 with and without Copper (25 µM) and levels of intracellular calcium was monitored, Cellular Recovery • Copper induce
Slide 48: Telomir-1 restores vision and retinal structure in AMD model
Telomir-1 restores vision, retinal structure, and reduces oxidative damage in AMD model In a dry AMD model, Telomir-1 achieved functional vision recovery and structural regeneration— marking the first oral regenerative candidate. • Restored central vision: light and movement responsiveness improved
Slide 49: Telomir-1 Restores Vision in AMD Model
Telomir-1™ Restores Vision in AMD Model Varying light response First Oral Therapy Showing Regenerative Effects in FDA- Surrogate AMD Model Study Overview • Model: 18-month-old Sen57wrn⁻/⁻ND6⁻/⁺ zebrafish — recapitulates dry AMD with central vision loss, retinal thinning, oxidative stress and ~15% mo
Slide 50: Telomir-1 Rebuilds Retinal Layers in AMD Model
Telomir-1™ Rebuilds Retinal Layers in AMD Model Whole retinal layers Telomir-1™ Restores Vision & Retinal Structure in AMD Model First Oral Therapeutic Showing Regenerative Effects in FDA-Surrogate-Driven Proof-of-Concept T E L O M I R P H A R M A . C O M Structural Regeneration • Full restoration o
Slide 51: Telomir-1 Rebuilds Retinal Layers: Percent Retinal Degeneration
Telomir-1™ Rebuilds Retinal Layers in AMD Model Percent retinal degeneration Telomir-1™ Restores Vision & Retinal Structure in AMD Model First Oral Therapeutic Showing Regenerative Effects in FDA-Surrogate-Driven Proof-of-Concept Structural Regeneration T E L O M I R P H A R M A . C O M • Marked imp
Slide 52: Telomir-1 Reverses Key Aging Markers in Werner Syndrome Model
Telomir-1 Reverses Key Aging Markers in Werner Telomer length normalization Syndrome Model Telomere length and DNA methylation patterns were normalized in Sen57wrn⁻/⁻ zebrafish—exceeding wild-type levels at higher doses. • Mutant zebrafish showed severe telomere shortening T E L O M I R P H A R M A
Slide 53: Telomir-1 Restores Physical and Cellular Health in Werner Syndrome Model
Restauration of lost muscle weight Telomir-1 Restores Physical and Cellular Health in Werner Syndrome Model 14-day oral treatment reverses muscle loss and oxidative stress in Sen57wrn⁻/⁻ zebrafish • Mutant fish displayed significant loss of body and T E L O M I R P H A R M A . C O M muscle mass • Te
Slide 54: Full Survival and Broad Rejuvenation in Werner Syndrome Model
Telomir-1 Achieves Full Survival and Broad Rejuvenation in Werner Syndrome Model 14-day treatment in Sen57wrn⁻/⁻ zebrafish reverses aging hallmarks and eliminates mortality Survival analysis – no animals died when treated with telomir-1 Study Model & Design • Model: Sen57wrn⁻/⁻ND6⁻/⁺ zebrafish T E L
Slide 55: Telomir-1 Restores Neuromotor Function in Wilson's Disease Model
Telomir-1™ Restores Neuromotor Function in Wilson’s Disease Model Telomir-1™ Reverses Multi-Organ Dysfunction in Wilson’s Disease Model Episodic tremor events Dose-Dependent Reversal of Neurological, Hepatic & Renal Damage in ATP7B ⁻/⁻ Zebrafish Study Overview • Model: ATP7B C271X⁻/⁻ zebrafish, repl
Slide 56: Telomir-1 Reverses Multi-Organ Dysfunction in Wilson's Disease Model
Telomir-1™ Reverses Multi-Organ Dysfunction in Wilson’s Disease Model Liver copper levels Dose-Dependent Reversal of Neurological, Hepatic & Renal Damage in ATP7B⁻/⁻ Zebrafish Hepatic & Renal Benefit • ~50% reduction in liver copper accumulation T E L O M I R P H A R M A . C O M • Histopathology sco
Slide 57: Pre-Clinical Research Summary
PRE-CLINICAL RESEARCH -SUMMARY Domain Main characteristics details Pharmacology Selective metal ion chelator Fe>Cu>>Zn ADME Absorption • Telomir-1 is rapidly absorbed in rat and dog with rapid elimination half-life T E L O M I R P H A R M A . C O M Metabolism • Was stable in mouse, rat, dog, monkey,
Slide 58: Anticipated Timeline for Telomir-1
ANTICIPATED TIMELINE FOR TELOMIR-1 2025 2025 2025 2026 T E L O M I R P H A R M A . C O M Q2 Q3 Q4 Q1 § GMP CMC (Chemistry, §GMP CMC (Chemistry, §Toxicology: Completion Formal § CMC (Chemistry, Manufacturing, and Controls): GMP Toxicology Manufacturing, and Manufacturing, and (Good Manufacturing Prac
Slide 59: Market Opportunity
MARKET OPPORTUNITY Summary of USEpidemiology The eligible patient pool analysis for Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions. T E L O M I R P H A R M A . C O M Total Eligible Total Diagnosed Treatment Population Addressable Prevalence R
Slide 60: Market Opportunity for Rare Diseases
MARKET OPPORTUNITY FOR RARE DISEASES Summary of USEpidemiology The eligible patient pool analysis for Telomir-1 highlights a potential large patient pool looking for potential treatments to their conditions. T E L O M I R P H A R M A . C O M Total Eligible Total Diagnosed Population Treatment Rate A
Slide 61: Growth Strategy
GROWTH STRATEGY Continue pre-clinical development of Telomir-1 across a range of diseases and progress into clinical development T E L O M I R P H A R M A . C O M Advance Telomir-1 through clinical development and FDA approval Identify additional product candidates and expand current candidates into
Slide 62: Investment Highlights
INVESTMENT HIGHLIGHTS Telomir-1 T E L O M I R P H A R M A . C O M TELOMIR-1 is novel Based on our pre- The Company’s goal is small molecule metal clinical studies to date to explore the potential ion regulator, with a we assemble of Telomir-1 starting broad potential to experimental evidences with o
Slide 63: Thank you.
Thank 100 SE 2nd Street you. Suite 2000 #1009 Miami, FL 33131 TelomirPharma.com
Telomir Pharmaceuticals — Investor Presentation (November 2025) on 6ix